SectorPharmaceutical
Established Date--
Listing Date05/11/2015
ExchangeNASDAQ Stock Exchange
Full-time Employees260
Fiscal Year Ends31/12
Security TypeCommon stock
Office address4930 Directors Place, Suite 500, San Diego, CA 92121
Business
IntroductionKura Oncology, Inc., was originally incorporated in Delaware in November 2007. They are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine to treat cancer. Their pipeline consists of small molecule product candidates targeting cancer signaling pathways where there are strong scientific and clinical reasons to improve outcomes, which they intend to combine with molecular or cellular diagnosis to identify patients most likely to respond to treatment. They are conducting clinical trials on three product candidates: ciftominib, tipifarnib and KO-2806.
